{
    "body": "Is imatinib an antidepressant drug?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20676553", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19110398", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22593820", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16403813", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22460758", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16566359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22487918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20442314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22035758", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21938530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15966213", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17554495", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22484890", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20726677", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20407930", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21607924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23394826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18506179", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22110503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21087500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22678007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19628568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22135725"
    ], 
    "triples": [
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/724", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3066", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/541", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2610", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/513", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/612", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/441", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/251", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/795", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3277", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/782", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2806", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A12798671", 
            "o": "Imatinib"
        }, 
        {
            "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17885052", 
            "o": "http://www.w3.org/2008/05/skos-xl#Label"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A12790183", 
            "o": "IMATINIB"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A1989038", 
            "o": "MeSH"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/relationontology/hasSideEffect", 
            "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
            "o": "http://linkedlifedata.com/resource/pubmed/mesh/Anxiety"
        }
    ], 
    "ideal_answer": [
        "No. Imatinib is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Chronic myelogenous leukemia (CML) and Gastrointestinal stromal tumor (GIST)."
    ], 
    "exact_answer": "no", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007202", 
        "http://www.biosemantics.org/jochem#4275840"
    ], 
    "type": "yesno", 
    "id": "51542e84d24251bc05000083", 
    "snippets": [
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 325, 
            "text": "Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery remains the elective treatment. We retrospectively compared two group of patients, who underwent surgery for GIST before and after Imatinib advent in order to analyze the recurrence and survival rate.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22487918", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1206, 
            "offsetInEndSection": 1368, 
            "text": "Adjuvant imatinib 400 mg/day for 3 years duration is a standard treatment in all patients with significant risk of recurrence following resection of primary GISTs", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1496, 
            "offsetInEndSection": 1585, 
            "text": "R1 surgery (versus R0) alone is not an indication for adjuvant imatinib in low-risk GIST.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1931, 
            "offsetInEndSection": 2005, 
            "text": "Treatment is not recommended in an imatinib-insensitive D842V-mutated GIST", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 310, 
            "offsetInEndSection": 701, 
            "text": "Prognostic factors such as tumor size, mitotic rate and presence of metastases may provide an indication for adjuvant imatinib mesylate (IM) treatment. Here we present a young patient with a large GIST with high-risk features who is in complete remission after surgical excision and adjuvant IM treatment. This patient is the only colon-located CD117-positive case where IM was administered.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678007", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 154, 
            "text": "Imatinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22460758", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1596, 
            "offsetInEndSection": 1686, 
            "text": "imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22135725", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 300, 
            "text": "Allogeneic hematopoietic stem cell transplantation (HSCT) is well-established as a potentially curative treatment for patients who have chronic myeloid leukemia. The success of imatinib and other tyrosine kinase inhibitors (TKI) as initial therapy has changed the treatment paradigm for this disease.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22035758", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1089, 
            "offsetInEndSection": 1219, 
            "text": "Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21938530", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1272, 
            "offsetInEndSection": 1440, 
            "text": "Ki67 correlated with time to recurrence (p=0.022). Ki67 >11% was taken as the indication to start imatinib chemotherapy (sensitivity 61.5%, specificity 92.0%, p=0.022).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607924", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 410, 
            "offsetInEndSection": 554, 
            "text": "Significant pharmacokinetic interactions have already been shown between St. John's Wort (SJW) and the anticancer drugs imatinib and irinotecan.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394826", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1386, 
            "offsetInEndSection": 1440, 
            "text": "for CML we analysed imatinib, dasatinib and nilotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 253, 
            "text": "Imatinib mesylate, an orally administered kinase inhibitor that targets the Kit (CD117) protein, currently has 10 approved indications including treatment of chronic myelogenous leukemia and metastatic gastrointestinal stromal tumors (GIST).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726677", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 539, 
            "offsetInEndSection": 903, 
            "text": "The drugs were assessed according to clinical evidence on efficacy and safety, based on Micromedex categorization, on systematic reviews and meta-analyses. Indications present in the legal documentation were compared to the indications approved by regulatory agencies. RESULTS: Bevacizumab, capecitabine, cetuximab, erlotinib, rituximab, imatinib, and temozolomide", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20676553", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 540, 
            "offsetInEndSection": 580, 
            "text": "Bcr-Abl, an oncogene responsible for CML", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20442314", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1442, 
            "offsetInEndSection": 1545, 
            "text": "Bcr-Abl-expressing cells showed resistance to death activated by spindle defects, reversed by imatinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20442314", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 275, 
            "offsetInEndSection": 399, 
            "text": "Imatinib, an oral tyrosine kinase inhibitor (TKI), is first-line treatment in patients with metastatic or unresectable GIST.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20407930", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 130, 
            "text": "Surgical indication for metastatic gastrointestinal stromal tumor (GIST) treated with imatinib is not yet established.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628568", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1097, 
            "offsetInEndSection": 1285, 
            "text": "Surgery of residual disease upon best clinical response seems associated with survival benefit compared with historical controls in similar patient collectives treated with imatinib alone.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628568", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 167, 
            "text": "To explore the effect of preoperative imatinib mesylate (IM) in patients with unresectable or locally advanced primary gastrointestinal stromal tumor (GIST)", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110398", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 725, 
            "offsetInEndSection": 1054, 
            "text": "The patient had been diagnosed 14 months earlier and had been submitted to surgery, followed by adjuvant radiotherapy and temozolomide-based chemotherapy. On clinical suspicion of recurrence 5 months later, magnetic resonance imaging (MRI) revealed a lesion at the site of preceded surgery, which was treated by imatinib mesylate", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17554495", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1512, 
            "offsetInEndSection": 1678, 
            "text": "Radical surgery remains the most effective method of GIST treatment. In inoperable/metastatic lesion the treatment of choice is tyrosinase kinase inhibitor--imatinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16566359", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 162, 
            "text": "Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403813", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 195, 
            "text": "Imatinib, an inhibitor of the tyrosine kinase activity of c-kit, was used as an adjuvant chemotherapy in two patients who underwent curative surgery for recurrent gastrointestinal stromal tumors.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15966213", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1206, 
            "offsetInEndSection": 1369, 
            "text": "Adjuvant imatinib 400 mg/day for 3 years duration is a standard treatment in all patients with significant risk of recurrence following resection of primary GISTs.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
            "endSection": "sections.0"
        }
    ]
}